Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers

Titilope Fasipe, MD, PhD

Researcher
Co-Director
Sickle Cell Program
Texas Medical Center
6701 Fannin St., Ste. 15210.27
Houston, Texas, United States

Dr. Titilope Fasipe’s goals are shaped by her desire to help children facing the hardships of a blood disorder. She is intrigued by the clinical challenges of non-malignant hematologic diseases, wherein particular patients with sickle cell disease continue to have significant co-morbid complications and decreased lifespan. Furthermore, Dr. Titilope Fasipe has been long passionate about the psychosocial barriers to care experienced by children with sickle cell, especially during the transitional years.

In addition to her academic role, Dr. Fasipe’s is actively involved in various sickle cell-focused community efforts targeted at understanding these challenges. At the state level, she was appointed at the first Texas Sickle Cell Advisory Committee (2016-2018) by the Executive Commissioner of the Texas Health and Human Services. At the local level, she is the current chair of the Houston Sickle Cell Collaborative – a joint effort between the Houston Health Department and organizations vested in sickle cell disease.

Dr. Fasipe’s research interests are focused on understanding barriers to transitioning youth with sickle cell to adult care. She desires to improve readiness to transition through active training and mentorship programs. Additionally, she wants to understand the factors related to patients with high care utilization patterns, in particular those with recurrent pain encounters. Dr. Fasipe is working to provide interventions to help improve pain management and hence, decrease the burden of high utilization.

 

Representative Publications:

Regional Anesthesia for Sickle Cell Disease Vaso-Occlusive Crisis: A Single-Center Case Series

Spinal Cord Compression: An Unusual Sequela of Sickle Cell Disease

Hospital Use and Mortality in Transition-Aged Patients With Sickle Cell Disease

Novel Dose Escalation to Predict Treatment With Hydroxyurea (NDEPTH): A Randomized Controlled Trial of a Dose-Prediction Equation to Determine Maximum Tolerated Dose of Hydroxyurea in Pediatric Sickle Cell Disease

 

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close